Advances in the Treatment of Autosomal Recessive Congenital Ichthyosis: A Look Towards the Repositioning of Drugs
November 2023
in “
Frontiers in pharmacology
”
Studysummary This review highlights the ongoing need for novel treatments for autosomal recessive congenital ichthyoses, suggesting that drug repositioning, utilizing existing medications or biologics, could provide more affordable and effective options for managing this lifelong skin condition. Our plain-language summary of this paper — not a Tressless recommendation.
The document discusses Autosomal recessive congenital ichthyoses (ARCI), a genetic skin disorder characterized by scaling and redness, which significantly impacts patients' quality of life. While topical treatments are commonly used for their convenience and affordability, oral retinoids are more effective but come with limitations. Since ARCI is a lifelong condition, there is a continuous need for new treatments. The review highlights drug repositioning as a promising approach to develop new, cost-effective therapies for ARCI by leveraging existing knowledge of drugs and biologics, potentially offering more accessible treatment options for patients.
